These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26440530)

  • 1. A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.
    Rouwendal GJ; van der Lee MM; Meyer S; Reiding KR; Schouten J; de Roo G; Egging DF; Leusen JH; Boross P; Wuhrer M; Verheijden GF; Dokter WH; Timmers M; Ubink R
    MAbs; 2016; 8(1):74-86. PubMed ID: 26440530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting.
    Meyer S; Nederend M; Jansen JH; Reiding KR; Jacobino SR; Meeldijk J; Bovenschen N; Wuhrer M; Valerius T; Ubink R; Boross P; Rouwendal G; Leusen JH
    MAbs; 2016; 8(1):87-98. PubMed ID: 26466856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo.
    Hsiao HC; Fan X; Jordan RE; Zhang N; An Z
    Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
    Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
    MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HER2 Cancer-Specific mAb, H
    Suzuki H; Ohishi T; Tanaka T; Kaneko MK; Kato Y
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39125956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring Site-Specific N-Glycosylation of HEK293 and Plant-Produced Human IgA Isotypes.
    Göritzer K; Maresch D; Altmann F; Obinger C; Strasser R
    J Proteome Res; 2017 Jul; 16(7):2560-2570. PubMed ID: 28516782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
    Brandsma AM; Ten Broeke T; Nederend M; Meulenbroek LA; van Tetering G; Meyer S; Jansen JH; Beltrán Buitrago MA; Nagelkerke SQ; Németh I; Ubink R; Rouwendal G; Lohse S; Valerius T; Leusen JH; Boross P
    Cancer Immunol Res; 2015 Dec; 3(12):1316-24. PubMed ID: 26407589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties.
    Nordstrom JL; Gorlatov S; Zhang W; Yang Y; Huang L; Burke S; Li H; Ciccarone V; Zhang T; Stavenhagen J; Koenig S; Stewart SJ; Moore PA; Johnson S; Bonvini E
    Breast Cancer Res; 2011; 13(6):R123. PubMed ID: 22129105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.
    Fan X; Brezski RJ; Fa M; Deng H; Oberholtzer A; Gonzalez A; Dubinsky WP; Strohl WR; Jordan RE; Zhang N; An Z
    Breast Cancer Res; 2012 Aug; 14(4):R116. PubMed ID: 22873525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
    Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating IgG effector function by Fc glycan engineering.
    Li T; DiLillo DJ; Bournazos S; Giddens JP; Ravetch JV; Wang LX
    Proc Natl Acad Sci U S A; 2017 Mar; 114(13):3485-3490. PubMed ID: 28289219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.
    Zhang N; Liu L; Dumitru CD; Cummings NR; Cukan M; Jiang Y; Li Y; Li F; Mitchell T; Mallem MR; Ou Y; Patel RN; Vo K; Wang H; Burnina I; Choi BK; Huber HE; Stadheim TA; Zha D
    MAbs; 2011; 3(3):289-98. PubMed ID: 21487242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
    Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
    Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced sialylation of a human chimeric IgG1 variant produced in human and rodent cell lines.
    Mimura Y; Kelly RM; Unwin L; Albrecht S; Jefferis R; Goodall M; Mizukami Y; Mimura-Kimura Y; Matsumoto T; Ueoka H; Rudd PM
    J Immunol Methods; 2016 Jan; 428():30-6. PubMed ID: 26627984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib.
    Chakraborty AK; Zerillo C; DiGiovanna MP
    Breast Cancer Res Treat; 2015 Aug; 152(3):533-44. PubMed ID: 26195122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity.
    Duong MN; Cleret A; Matera EL; Chettab K; Mathé D; Valsesia-Wittmann S; Clémenceau B; Dumontet C
    Breast Cancer Res; 2015 Apr; 17(1):57. PubMed ID: 25908175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
    Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
    PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities.
    Kurogochi M; Mori M; Osumi K; Tojino M; Sugawara S; Takashima S; Hirose Y; Tsukimura W; Mizuno M; Amano J; Matsuda A; Tomita M; Takayanagi A; Shoda S; Shirai T
    PLoS One; 2015; 10(7):e0132848. PubMed ID: 26200113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
    Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
    Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.